This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
269,00 € per year
only 22,42 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
Data are available on the basis of institutional review board-approved data request in alignment with applicable data protection regulations.
References
Sekeres MA, Taylor J. Diagnosis and treatment of myelodysplastic syndromes: a review. JAMA. 2022;328:872–80. https://doi.org/10.1001/jama.2022.14578.
Locatelli F, Strahm B. How I treat myelodysplastic syndromes of childhood. Blood. 2018;131:1406–14. https://doi.org/10.1182/blood-2017-09-765214.
Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17:277–82. https://doi.org/10.1038/sj.leu.2402765.
Hasle H, Niemeyer CM. Advances in the prognostication and management of advanced MDS in children. Br J Haematol. 2011;154:185–95. https://doi.org/10.1111/j.1365-2141.2011.08724.x.
Strahm B, Nöllke P, Zecca M, Korthof ET, Bierings M, Furlan I, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia. 2011;25:455–62. https://doi.org/10.1038/leu.2010.297.
de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129:1753–62. https://doi.org/10.1182/blood-2016-06-724500.
Potter VT, Iacobelli S, van Biezen A, Maertens J, Bourhis JH, Passweg JR, et al. Comparison of intensive chemotherapy and hypomethylating agents before allogeneic stem cell transplantation for advanced myelodysplastic syndromes: a study of the myelodysplastic syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2016;22:1615–20. https://doi.org/10.1016/j.bbmt.2016.05.026.
de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000;110:620–30. https://doi.org/10.1046/j.1365-2141.2000.02200.x.
Sasaki H, Manabe A, Kojima S, Tsuchida M, Hayashi Y, Ikuta K, et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia. 2001;15:1713–20. https://doi.org/10.1038/sj.leu.2402271.
Woods WG, Barnard DR, Alonzo TA, Buckley JD, Kobrinsky N, Arthur DC, et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children’s Cancer Group. J Clin Oncol. 2002;20:434–40. https://doi.org/10.1200/JCO.2002.20.2.434.
Gao J, Hu Y, Gao L, Xiao P, Lu J, Hu S. The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years’ experience of a single center. BMC Pediatr. 2022;22:312 https://doi.org/10.1186/s12887-022-03376-1.
Acknowledgements
This work was supported by the CAMS Innovation Fund for Medical Sciences grants (CIFMS) (2023-I2M-C&T-B-106 (WY), 2021-I2M-1-003 (WY), 2021-I2M-1-041 (YW), 2022-I2M-1-022 (XZ)), the National Natural Science Foundation of China (82270144 (XZ)), and the Health and Wellness Development Promotion grants-Huiyu Oncology Research grants (008 (WY)).
Author information
Authors and Affiliations
Contributions
XW was responsible for analyzing data, interpretation of results, visualization of data and results in figures and tables, and writing the manuscript. CL and YC was responsible for collecting data and provided conceptual input. YW, WA, XL, LL, FL, LZ, YZ, XC, YC and YG provided patient data. XZ and WY designed the research and reviewed the manuscript. All authors agreed to submit the final version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Exemption of informed consent approved by the Ethics Committee of Blood Diseases Hospital, Chinese Academy of Medical Sciences (IIT2021009-EC-1). Written informed consent was obtained from the guardian of the patient.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
41409_2024_2488_MOESM1_ESM.docx
Efficacy and Prognostic Assessment of Chemotherapy-Bridged Transplantation in Pediatric Patients with Advanced Myelodysplastic Syndromes
Rights and permissions
About this article
Cite this article
Wang, X., Liu, C., Chen, Y. et al. Efficacy and prognostic assessment of chemotherapy-bridged transplantation in pediatric patients with advanced myelodysplastic syndromes. Bone Marrow Transplant 60, 403–405 (2025). https://doi.org/10.1038/s41409-024-02488-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-024-02488-9
